RxDoctor Payments Data

Jordan Comstock

Ophthalmology · Dallas, TXNPI 1619465374

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 46 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$503
  • Sun Pharmaceutical Industries Inc.$321
  • Alcon$285
  • Harrow Eye, LLC$187
  • Tarsus Pharmaceuticals, Inc.$147
  • Axogen$144
  • plus $341 from 4 others

What the payments were for

  • Food & beverage$1,928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,928 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$283,351
Medicare patients
575
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf54$40,455
RestasisCyclosporine31$39,329
VevyeCyclosporine46$29,716
XiidraLifitegrast23$26,447
Prednisolone Acetate350$16,888
MoxifloxacinMoxifloxacin Hcl284$7,969
ValacyclovirValacyclovir Hcl64$3,493
Fluorometholone34$2,846
Loteprednol Etabonate21$2,353
Ketorolac Tromethamine55$1,324
Doxycycline Hyclate25$896
Brimonidine Tartrate15$672
Acyclovir22$438
Tobramycin16$177
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra$503$66,90277 claims
Harrow Eye, LLCVevye$187$29,71646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →